C12N 2740/16134
Use of virus or viral component as vaccine
Official title: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2740/16134 (Use of virus or viral component as vaccine) appears on 602 US grants and 932 published applications in this corpus.
Search patents in C12N- Granted patents
- 602
- Published applications
- 932
- Assignees
- 444
- Inventors
- 1,484
- Latest grant
- 25 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1990 | 1 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 2 | 0 |
| 1995 | 0 | 0 |
| 1996 | 3 | 0 |
| 1997 | 4 | 0 |
| 1998 | 20 | 0 |
| 1999 | 12 | 0 |
| 2000 | 12 | 0 |
| 2001 | 8 | 5 |
| 2002 | 14 | 24 |
| 2003 | 10 | 31 |
| 2004 | 9 | 45 |
| 2005 | 10 | 34 |
| 2006 | 17 | 40 |
| 2007 | 13 | 33 |
| 2008 | 14 | 32 |
| 2009 | 15 | 45 |
| 2010 | 21 | 40 |
| 2011 | 23 | 41 |
| 2012 | 21 | 51 |
| 2013 | 14 | 25 |
| 2014 | 24 | 38 |
| 2015 | 27 | 43 |
| 2016 | 25 | 52 |
| 2017 | 34 | 40 |
| 2018 | 42 | 33 |
| 2019 | 38 | 50 |
| 2020 | 34 | 39 |
| 2021 | 31 | 51 |
| 2022 | 26 | 31 |
| 2023 | 20 | 27 |
| 2024 | 27 | 32 |
| 2025 | 13 | 26 |
| 2026 | 18 | 24 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Rapid elicitation of broadly neutralizing bovine antibodies to HIV Env25 Aug 2026US 12,715,907 B2International AIDS Vaccine Initiative
- Methods and compositions for inducing an immune response using conserved element constructs18 Aug 2026US 12,709,635 B2The United States of America, as represented by the Secretary, Department of Health and Human Services
- HIV immunotherapy with no pre-immunization step18 Aug 2026US 12,709,753 B2American Gene Technologies International Inc.
- Modified envelope protein of human immunodeficiency virus and use thereof4 Aug 2026US 12,697,383 B2Xiamen Innovax Biotech Co., Ltd.
- Recombinant HIV Env polypeptides and their uses14 Jul 2026US 12,679,869 B2International AIDS Vaccine Initiative
- Improved alum-anchored immunogens1 Oct 2026US 2026/0295039 A1Massachusetts Institute of Technology
- Compositions comprising mrnas encoding hiv-1 membrane proximal external region (mper) peptides24 Sep 2026US 2026/0285910 A1
- Methods of producing hiv-1 envelope glycoproteins and guanosine microparticles thereof24 Sep 2026US 2026/0285913 A1
- Immunogenic trimers17 Sep 2026US 2026/0273042 A1International AIDS Vaccine Initiative
- Dual-germline antibody engager hiv-1 envelope chimeric immunogens27 Aug 2026US 2026/0248907 A1The United States of America, as represented by the Secretary, Department of Health and Human Services
Most cited
By later US patents
- Genetic immunization277US 5,593,972 AThe Trustees of the University of Pennsylvania · 1997
- Albumin fusion proteins comprising GLP-1 polypeptides198US 7,141,547 B2Human Genome Sciences, Inc. · 2006
- Compositions and methods for delivery of genetic material184US 5,739,118 AApollon Inc. · 1998
- Genetic immunization137US 5,817,637 AThe Trustees of the University of Pennsylvania · 1998
- Compositions and methods for delivery of genetic material132US 5,962,428 AApollon Inc. · 1999